

INOVIO BIOMEDICAL CORP
Form 10-Q
November 09, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2006

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-14888

INOVIO BIOMEDICAL CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware

33-0969592

Edgar Filing: INOVIO BIOMEDICAL CORP - Form 10-Q

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

11494 SORRENTO VALLEY ROAD
SAN DIEGO, CALIFORNIA 92121-1318
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)

(858) 597-6006
(COMPANY S TELEPHONE NUMBER, INCLUDING AREA CODE)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer as defined in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the registrant s Common Stock, par value \$0.001 per share, was 35,530,844 as of November 6, 2006.

INOVIO BIOMEDICAL CORPORATION

FORM 10-Q

For the Quarterly Period Ended September 30, 2006

INDEX

	Page
<u>Part I</u> <u>Financial Information</u>	3
<u>Item 1.</u> <u>Financial Statements</u>	3
a) <u>Condensed Consolidated Balance Sheets as of</u> <u>September 30, 2006 (Unaudited) and December 31,</u> <u>2005</u>	3
b) <u>Condensed Consolidated Statements of Operations for</u> <u>the Three and Nine Months Ended September 30, 2006</u> <u>and 2005 (Unaudited)</u>	4
c) <u>Condensed Consolidated Statements of Cash Flows for</u> <u>the Nine Months Ended September 30, 2006 and 2005</u> <u>(Unaudited)</u>	5
d) <u>Notes to Condensed Consolidated Financial Statements</u> <u>(Unaudited)</u>	6
<u>Item 2.</u> <u>Management's Discussion and Analysis of Financial Condition and Results</u> <u>of Operations</u>	15
<u>Item 3.</u> <u>Quantitative and Qualitative Disclosures About Market Risk</u>	34
<u>Item 4.</u> <u>Controls and Procedures</u>	34
<u>Part II</u> <u>Other Information</u>	35
<u>Item 1.</u> <u>Legal Proceedings</u>	35
<u>Item 1A.</u> <u>Risk Factors</u>	35
<u>Item 2.</u> <u>Unregistered Sale of Equity Securities and Use of Proceeds</u>	39
<u>Item 3.</u> <u>Default Upon Senior Securities</u>	39
<u>Item 4.</u> <u>Submission of Matters to a Vote of Security Holders</u>	39
<u>Item 5.</u> <u>Other Information</u>	39
<u>Item 6.</u> <u>Exhibits</u>	39
<u>Signatures</u>	40

Part I. Financial Information

Item 1. Financial Statements

INOVIO BIOMEDICAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2006 (Unaudited)	December 31, 2005
ASSETS		
Cash and cash equivalents	\$ 1,939,893	\$ 17,166,567
Short-term investments	5,700,000	
Accounts receivable	304,090	284,171
Prepaid expenses and other current assets	1,157,842	870,169
Total current assets	9,101,825	18,320,907
Fixed assets, net	459,404	375,613
Patents and other assets, net	2,375,549	2,148,090
Goodwill	4,290,594	4,290,594
Intangible assets, net	3,675,000	3,843,750
Total assets	\$ 19,902,372	\$ 28,978,954
LIABILITIES AND STOCKHOLDERS EQUITY		
Accounts payable and accrued expenses	\$ 1,444,794	\$ 1,864,935
Accrued clinical trial expenses	614,468	1,064,497
Deferred revenue	675,450	1,206,443
Total current liabilities	2,734,712	4,135,875
Deferred rent	245,851	285,875
Deferred tax liabilities	1,029,000	1,076,250
Long-term liabilities		10,206
Total liabilities	4,009,563	5,508,206